Description
The abstract reports that disease reversal continues longer than the actual huntingtin reduction, suggesting unknown downstream mechanisms maintain therapeutic benefit. Understanding this temporal dissociation could reveal new therapeutic targets and optimize treatment intervals.
Gap type: unexplained_observation Source paper: Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. (None, None, PMID:22726834)
Resolution criteria
Resolved when an evidence artifact identifies the downstream mechanisms sustaining HD reversal beyond huntingtin knockdown, with one of: (1) gene expression profiling (RNA-seq of striatum at >=3 timepoints post-treatment) identifying >=5 sustained differentially expressed genes (DEGs) that persist >=30 days after huntingtin levels return to baseline, with pathway analysis (KEGG/GO) linking these to neuroprotection or circuit remodeling; (2) proteomic profiling (TMT-MS or label-free) identifying >=3 sustained protein abundance changes in striatal tissue >=30 days post-treatment, with functional validation (Western blot or targeted MS) confirming persistence; (3) epigenetic profiling (ATAC-seq or ChIP-seq for H3K27ac) identifying sustained chromatin state changes in striatal neurons >=30 days post-treatment. The artifact must include quantitative thresholds (>=2-fold change, FDR < 0.05, n >= 4 animals) and link findings to the huntingtin synthesis mechanism in the KG.